1 Subjects: “...Biological Products / therapeutic use...”

2 Subjects: “...Biological Products / therapeutic use...”

3 “.... The production of methamphetamine is dangerous and produces large volumes of toxic chemical waste. In 2006...”

4 “.... The production of methamphetamine is dangerous and produces large volumes of toxic chemical waste. In 2006...”

5 “... to autoantibody production and abnormal B lymphocyte function. In Canada, the Common Drug Review (CDR) committee...”

6 “... to autoantibody production and abnormal B lymphocyte function. In Canada, the Common Drug Review (CDR) committee...”

7 “... microvascular leakage, and lessen mucus production. Although benefit of its use in CF has not been proven, ICS...”

8 “... microvascular leakage, and lessen mucus production. Although benefit of its use in CF has not been proven, ICS...”

9

10

11 “...In 2017, CADTH produced a Rapid Response report summarizing evidence on the clinical effectiveness...”

12 “...In 2017, CADTH produced a Rapid Response report summarizing evidence on the clinical effectiveness...”

13

14

15 “...The Eczema Society of Canada has a Seal of Acceptance program "where products are reviewed to earn...”

16 “...The Eczema Society of Canada has a Seal of Acceptance program "where products are reviewed to earn...”

17 “... products. These products use antimicrobial agents such as triclosan, chlorhexidine, iodophors or quaternary...”

18 “... products. These products use antimicrobial agents such as triclosan, chlorhexidine, iodophors or quaternary...”

19 “...), and received a recommendation of "do not list". CADTH has previously produced a Rapid Response Summary...”

20 “...), and received a recommendation of "do not list". CADTH has previously produced a Rapid Response Summary...”